- By Shreyansh Mangla
- Mon, 13 Oct 2025 04:54 PM (IST)
- Source:JND
Rubicon Research IPO: A pharma company, Rubicon Research, is selling its shares to the public for the first time by holding an IPO. Rubicon Research IPO opened for subscription on October 9 and today is the last day for investors to buy these shares before they hit the official stock market. The company plans to raise Rs 1,377.50 crore. While some of these funds will go to the company for growth (fresh issue), some will go to the original owners who are planning to sell their existing shares (offer for sale).
Rubicon Research IPO: Key IPO Details
Price Per Share (PPS): The company has set the price between Rs 461 and Rs 485 per share, keeping the bidding range within this price range.
Rubicon Research IPO: GMP (Grey Market Premium)
There is a lot of excitement around the IPO as the stock's GMP stands at Rs 110 per share, signaling the popularity of the stock.
Rubicon Research IPO: Subscription Status
The IPO has been oversubscribed by over 48 times by 4.25 PM on October 13. There has been a high demand from retail investors as they applied for 12 times the shares set aside for them. Wealthy individuals (NII) applied for a massive 51 times their quota, while QIBs (Qualified Institutional Buyers) such as mutual funds, applied for 59 times their portion.
Rubicon Research IPO: Subscription Dates
The IPO opened for subscription on Thursday, October 9. The last date to apply for these shares is October 13, 2025.
Rubicon Research IPO: Allotment Dates
Investors can find out if they were allotted the shares on October 14.
Rubicon Research IPO: Listing Date
The Rubicon Research shares will debut on the BSE and NSE on October 16.
About Rubicon Research
Rubicon Research is a pharmaceutical company that started in 1999 in Thane, India. It focuses on creating its own medicine in its own manufacturing hub, through intellectual property or IP. These are unique in structure and company has lot of secret patents. The company specialises in making specialty drugs because.
(Disclaimer: This information is for learning purposes only and is not financial advice)